SG#WUXI RC2608C

BlackRock Reduces Stake in Wuxi Biologics H-shares to 4.51%

Nordic Nanovector Raises Nearly HK$200 Million Through Rights Issue to WuXi Biologics

Easton Securities Maintains Buy Rating on Wuxi Biologics

J.P. Morgan Raises Wyeth Biologics' Forecast and Target Price

Morgan Stanley Raises Target Price for Wuxi Biologics to 50 HKD

WuXi Biologics Anticipates 16.7% Revenue Growth to 21.79 Billion Yuan in 2025; Gross Margin to Increase by 5 Percentage Points to 46%

WuXi Biologics Reports Preliminary Full Year Net Profit Exceeding Expectations

WuXi Biologics Anticipates Revenue and Gross Margin Growth in 2025

WuXi Biologics Signs Innovative Tri-Specific TCE Development Agreement with Vertex Pharmaceuticals

WuXi Biologics Signs License and Research Agreement for Tri-specific T-cell Engager with Vertex Pharmaceuticals

WuXi Biologics and Sunovian Announce Strategic Collaboration on SND006 Process Development and Manufacturing

Morgan Stanley Reduced Stake in Wuxi Biologics (Cayman)

CLSA Report: Wuxi Biologics Outperforms Peers

WuXi Biologics and WuXi ChemPartner to Acquire at Least 60% of Tonox

CICC Maintains Buy Rating on Wuxi Biologics (Cayman)

Multiple HK-listed Companies Announce Major Updates

Major Wuxi Biologics Shareholder Sells Existing Shares

Wu Xiaosheng, CEO of WuXi Biologics, Speaks at JPM Healthcare Conference

Citi Group Launches Voluntary Cash Offer to Acquire eXiao Technology Cayman

WuXi Biologics and Zai Lab Sign TCE Research Collaboration Agreement

HKC INT'L RTS

HANG YICK RTS

TIANBAO ENERGY

CHERISH SUN

AGTECH HOLDINGS

KONG SUN HOLD

KO YO GROUP

SINO GAS HLDGS

NE ELECTRIC

HK ENT INTL

513130

03033

02269

03032

01211

03067

002594

STECH

00285

00HSI

Hong Kong stocks showed significant gains in the morning session, with the Hang Seng Index rising 605 points or 2.3% to 27,019 points. The National Index increased by 224 points, and the Hang Seng Tech Index rose by 173 points. Export, technology, and commodity stocks generally rose, with a total turnover of HKD 106.45 billion. BYD ELECTRONIC, Sunny Optical, and WUXI BIO performed strongly, and the decline of the US dollar also boosted commodity stocks

AASTOCKS

Huatai-PB CSOP Hang Seng Technology ETF(QDII)

CSOP HS TECH

WUXI BIO

HSTECH ETF

BYD COMPANY

ISHARESHSTECH

Hang Seng TECH Index

BYD ELECTRONIC

Hang Seng Index

"Hong Kong Stocks" Hang Seng Index rises 605 points in half a day, with export, technology, and commodity stocks up; AI and robotics stocks pull back

02513

09988

03690

02359

The Hong Kong stock market opened higher in the morning, with the Hang Seng Index rising 385 points to 26,798 points, and the National Index and Hang Seng TECH Index increasing by 131 points and 92 points, respectively. E-commerce stocks such as Alibaba and JD opened higher, while technology stocks Tencent, Meituan, and NetEase also saw gains. AI model stock KNOWLEDGE ATLAS opened down 13.8% due to issues. Export stocks such as Creative Technology and SHENZHOU INTL opened higher, and pharmaceutical stocks WUXI BIO and WUXI APPTEC also rose. Commodity prices increased, leading to a general rise in related resource stocks

KNOWLEDGE ATLAS

BABA-W

MEITUAN

SHENZHOU INTL

JD-SW

Alibaba

WUXI APPTEC

TENCENT

FI CSOP HSI

FI2CAMNDQ100

FL2 CSOP HSI

China Southern Hang Seng ETF

FI2 CSOP HSI

"Hong Kong Stocks" The Hang Seng Index opened high at 385 points, with technology, export, and resource stocks rising, while AI model stocks retraced

560600

159837

588130

520690

520880

159615

588250

512290

159316

516930

516500

588860

159849

159102

159859

513120

WXXWY

CANbridge Pharmaceuticals Inc. has announced a subscription agreement to issue 84,033,613 new shares at HK$2.38 each, raising approximately HK$199 million. The shares will be sold to a Hong Kong limited partnership owned by WuXi Biologics, at a discount to market prices. Proceeds will be used for working capital, R&D, and settling trade payables. The transaction is subject to regulatory approval and reflects ongoing support from WuXi Biologics. The latest analyst rating for CANbridge stock is a Buy with a target price of HK$3.00.

Tip Ranks

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Southern Hang Seng Biotech ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Penghua CSI HK Connect Health Care Composite ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Tianhong CNI BIOMEDICINE ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI 300 Health Care ETF

WuXi Biologics

CANBRIDGE-B

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

CANbridge to Raise HK$199 Million via Discounted Share Subscription Backed by WuXi Biologics Unit

01698

Hong Kong stocks fell 1.7% to 26,588, marking a second consecutive session of losses due to Wall Street's decline amid AI disruption concerns. China's new home prices dropped 3.3% year-on-year in January, the largest decrease in seven months, impacting market sentiment. All sectors declined, particularly financials, consumer names, and tech. Notable declines included Tencent Music (-9.2%) and Wuxi Biologics (-4.2%). Despite these losses, reports of delayed U.S. tech security measures provided some support. The market showed little change for the week, with trading paused for the Lunar New Year holiday.

- Hong Kong stocks fell 446 points, or 1.7%, to 26,588, influenced by a decline on Wall Street amid AI disruption concerns.  
- China's new home prices decreased by 3.3% year-on-year in January, the largest drop in seven months, impacting property market stability and investor sentiment.  
- Key stocks such as Tencent Music and Wuxi Biologics experienced significant losses, while reports of delayed U.S. tech security measures provided some support ahead of the upcoming U.S.-China summit.

Trading Economics

TME-SW

Tencent Music

Hong Kong Shares Under Pressure, Weekly Performance Muted

Bank of America Securities released a research report, indicating that WUXI BIO is expected to see revenue growth of 16.7% to 21.8 billion yuan in 2025, with gross margin improving to 46%. Net profit is expected to be 5.7 billion, representing a year-on-year growth of 45.3%. The firm raised its target price from HKD 41.8 to HKD 47, maintaining a "Neutral" rating

"Big Banks" Bank of America Securities: WUXI BIO's earnings surprise is stable, raising target price to 47 yuan

00020

09899

09961

MPNGY

603259

The Hong Kong stock market was under pressure in the morning session, with the Hang Seng Index down 242 points, closing at 27,023 points. The National Index fell by 89 points, and the Hang Seng Tech Index dropped by 92 points. Technology stocks generally declined, with Trip.com, Meituan, and NetEase experiencing significant losses. SenseTime rose 5.2% against the trend. Market expectations for a Federal Reserve rate cut have cooled, leading to a slight decline of 66 points in the Dow Jones Industrial Average

SENSETIME-W

NETEASE MUSIC

TRIP.COM-S

Meituan

WuXi AppTec

NTES-S

NetEase

"Hong Kong Stocks" Hang Seng Index fell 242 points in the half-day, with technology investment stocks leading the decline, while domestic property and WuXi AppTec stocks performed well

02268

Nomura's research report indicates that WUXI BIO is expected to see a revenue increase of 16.7% to RMB 21.8 billion in 2025, exceeding market expectations. The gross margin is expected to improve to 46%, and net profit is projected to grow by 45.3% to RMB 5.7 billion. The firm has raised the target price to HKD 50.54 and maintains a "Buy" rating, believing that its subsidiary WUXI XDC will make a significant contribution to revenue growth

WUXI XDC

Nomura raises WUXI BIO's target price to 50.54 yuan, with preliminary annual performance exceeding expectations

01876

The Hong Kong stock market showed a weak performance in the early session, with the Hang Seng Index opening down 55 points at 27,210 points. Technology stocks generally declined, with MEITUAN opening down 2.5%, Alibaba down 1.4%, and Tencent down 2%. NetEase's net profit fell short of expectations, leading to a 1.4% drop in its stock price. BUD APAC's net profit fell by 32.6% last year, resulting in a 2.1% decline in its stock price. In contrast, WUXI BIO opened up 2.7%, making it the best-performing blue-chip stock

BUD APAC

"Hong Kong Stocks" The Hang Seng Index opened 55 points lower, Netease and Bud APAC declined, WUXI BIO rose

WuXi XDC Cayman Inc. has launched a voluntary conditional cash offer to acquire all remaining shares of BioDlink not already owned by WuXi XDC and its concert parties. The offer includes the cancellation of all outstanding share options of BioDlink. This initiative follows a joint announcement by WuXi XDC, WuXi Biologics, and BioDlink to consolidate ownership in BioDlink.

Reuters

WuXi XDC Launches Cash Offer to Acquire All Remaining Shares of BioDlink

HSAI

The Hang Seng Index rose 82 points (0.3%) to close at 27,266, marking its third consecutive gain, driven by broad sector advances and positive sentiment from China's central bank's commitment to boost domestic demand. However, concerns over industrial overcapacity and weak consumption led to a trimming of morning gains. Notable stock movements included Hesai Group (+6.4%), SenseTime (+2.9%), and WuXi Biologics (+3.6%), while SMIC fell 2.7% amid industry concerns.

- The Hang Seng Index rose 82 points, or 0.3%, to close at 27,266, continuing its upward trend amid broad sector gains.  
- The market was buoyed by China's central bank's commitment to support domestic demand, although concerns about industrial overcapacity and weak consumption dampened morning gains.  
- Hesai Group and SenseTime saw significant increases after being added to the MSCI China Index, while SMIC experienced a decline following fears of an AI-driven memory chip shortage.

Hesai

Hang Seng Trims Gains at Close

Citi released a research report stating that WuXi Biologics is expected to significantly exceed market expectations for net profit in the second half of 2025, with revenue expected to grow by 17% year-on-year and net profit increasing by 38% to 2.6 billion RMB. Adjusted net profit is expected to rise by 31% to 3.7 billion RMB, with gross margin improving by 6.2 percentage points to 48.8%. The firm maintains WuXi Biologics as a preferred stock, with a target price of 48.5 RMB and a rating of "outperform."

ChinaAMC SSE Health Care ETF Initiating Fund

In "The Big Banks," Citigroup: WuXi Biologics' net profit in the second half of the fiscal year far exceeds expectations, continuing to be the industry's top pick

WuXi BIO expects a 46% increase in net profit last year, exceeding RMB 4.9 billion, with a revenue growth of 16%. CHINA LIT issued a profit warning, expecting a full-year loss to widen to RMB 750 million to 850 million, mainly due to goodwill impairment. Leading Intelligent's new stock debut performed well, with a maximum gain of RMB 74. SMIC's profit grew by 60.66% last quarter, with sales revenue of USD 2.48 billion. ZEEKR released the world's first general-purpose warehouse robot Gino 1. Baoshan International's January revenue decreased by 32.5% year-on-year

Tasty Money

CHINA LIT

[Daily Announcement] WUXI BIO (2269) expects a 46% increase in net profit last year, CHINA LIT (772) issues a profit warning, expecting an expanded annual loss

The Hang Seng Index opened higher, refreshing its nearly four-year high; Tencent's performance exceeded expectations, receiving collective bullish calls from major banks; Chip stocks strengthened on the logic of domestic substitution, with SMIC leading the gains; Ping An's stake increase in China Taiping H-shares ignited the insurance sector; Cryptocurrency concept stocks surged as Bitcoin hit a new high; In the pharmaceutical sector, Jingtai Holdings reported its first profit, rising over 11%, while East Buy saw a sudden 12% increase.

Tencent

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Ping An Insurance

PING AN

PING AN-R

Ping An Ins HK SDR2to1

Ping An

SMIC

SMIC HK SDR 5to1

CPIC

CHINA TAIPING

SUNSHINE INS

Life and Health Insurance

REMEGEN

RemeGen

BEONE MEDICINES

BeOne Medicines

Beigene

HUA HONG SEMI

Hua Hong

INNOCARE

InnoCare Pharma

GRANDSHORES

AKESO

HORIZONROBOT-W

ZA ONLINE

SINOHOPE TECH

GUOTAI JUNAN I

XTALPI

Life Sciences Tools and Services

XL2CSOPHSTECH

Semiconductors

LINEKONG

INNOVENT BIO

OKG TECH

Hot Trades in Hong Kong Stocks (8.14) | Hang Seng Index Hits Four-Year High at Opening, Morgan Stanley Says Foreign Capital Accelerated Inflows into Chinese Stock Market in July

SG#WUXI RC2608C(55799.HK)

"Hong Kong Stocks" Hang Seng Index rises 605 points in half a day, with export, technology, and commodity stocks up; AI and robotics stocks pull back

"Hong Kong Stocks" The Hang Seng Index opened high at 385 points, with technology, export, and resource stocks rising, while AI model stocks retraced

CANbridge to Raise HK$199 Million via Discounted Share Subscription Backed by WuXi Biologics Unit

Hong Kong Shares Under Pressure, Weekly Performance Muted

"Big Banks" Bank of America Securities: WUXI BIO's earnings surprise is stable, raising target price to 47 yuan